New combo aims to keep advanced lung cancer in check
NCT ID NCT05613413
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs (cabozantinib and pembrolizumab) as ongoing treatment can help keep advanced squamous lung cancer from growing. It is for people whose cancer was controlled after initial chemotherapy plus immunotherapy. About 36 adults will participate to see how long the cancer stays stable and what side effects occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SQUAMOUS NON-SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ryan Nguyen
RECRUITINGChicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.